From bench to bedside: the history and progress of CAR T cell therapy

Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for the treatment of pediatric and young adult patients with relapsed or refractory acute lymphocytic leukemia. As of April...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitra, Aroshi, Barua, Amrita, Huang, Luping, Ganguly, Siddhartha, Feng, Qin, He, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225594/
https://www.ncbi.nlm.nih.gov/pubmed/37256141
http://dx.doi.org/10.3389/fimmu.2023.1188049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225594/
https://www.ncbi.nlm.nih.gov/pubmed/37256141
http://dx.doi.org/10.3389/fimmu.2023.1188049

Ejemplares similares